标题
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
作者
关键词
-
出版物
SCIENCE
Volume 373, Issue 6557, Pages 931-936
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2021-07-20
DOI
10.1126/science.abg5827
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor
- (2021) Amornrat O'Brien et al. VIROLOGY
- Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
- (2021) Jim Baggen et al. NATURE GENETICS
- A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry
- (2021) Yunkai Zhu et al. Nature Communications
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
- (2021) Jerzy Osipiuk et al. Nature Communications
- Emerging coronaviruses: Genome structure, replication, and pathogenesis
- (2020) Yu Chen et al. JOURNAL OF MEDICAL VIROLOGY
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
- (2020) Xiaobo Yang et al. Lancet Respiratory Medicine
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- The Development of Coronavirus 3C-Like Protease (3CLpro) Inhibitors from 2010 to 2020
- (2020) Yuzhi Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography
- (2020) Daniel W. Kneller et al. Nature Communications
- Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay
- (2020) Heather M. Froggatt et al. JOURNAL OF VIROLOGY
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2020) Wayne Vuong et al. Nature Communications
- Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
- (2020) William M. Schneider et al. CELL
- Coxsackievirus B3 Responds to Polyamine Depletion via Enhancement of 2A and 3C Protease Activity
- (2019) Courtney N. Dial et al. Viruses-Basel
- Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins
- (2019) Miguel Angel Muñoz-Alía et al. Viruses-Basel
- Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
- (2019) Jesus S. Mora et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- A novel phosphoserine motif in the LCMV matrix protein Z regulates the release of infectious virus and defective interfering particles
- (2016) Christopher M. Ziegler et al. JOURNAL OF GENERAL VIROLOGY
- The Lymphocytic Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of Defective Interfering Particles
- (2016) Christopher M. Ziegler et al. PLoS Pathogens
- Masitinib for the treatment of mild to moderate Alzheimer’s disease
- (2015) Jaume Folch et al. Expert Review of Neurotherapeutics
- Masitinib for the treatment of mild to moderate Alzheimer’s disease
- (2015) Jaume Folch et al. Expert Review of Neurotherapeutics
- Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings
- (2013) Hyun Lee et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?
- (2013) Ilaria Marech et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Improved crystallographic models through iterated local density-guided model deformation and reciprocal-space refinement
- (2012) Thomas C. Terwilliger et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
- (2012) Patrick Vermersch et al. BMC Neurology
- The Tyrosine Kinase Inhibitor Masitinib Blunts Airway Inflammation and Improves Associated Lung Mechanics in a Feline Model of Chronic Allergic Asthma
- (2012) Tekla M. Lee-Fowler et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- High-throughput protein purification and quality assessment for crystallization
- (2011) Youngchang Kim et al. METHODS
- Molecular replacement withMOLREP
- (2009) Alexei Vagin et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- MolProbity: all-atom structure validation for macromolecular crystallography
- (2009) Vincent B. Chen et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics
- (2009) M. Humbert et al. ALLERGY
- Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
- (2009) J.C. Soria et al. EUROPEAN JOURNAL OF CANCER
- Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds
- (2009) Cheng-Chung Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
- (2009) K.A. Hahn et al. JOURNAL OF VETERINARY INTERNAL MEDICINE
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
- (2008) Arun K. Ghosh et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation